INTRODUCTION: T2-weighted and gadolinium enhanced T1-weighted MRI scans measure plaque burden and breakdown of the blood-brain barrier, respectively, in multiple sclerosis (MS) lesions. These have become widely used outcome measures for monitoring disease activity in clinical trials and clinical practice. However, their use as surrogates or biomarkers for disability and relapses, key clinical outcome measures, has remained incompletely validated. METHODS: In a clinical trial database compris...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
MRI as an outcome in multiple sclerosis clinical trials.
If you are the owner of this record, you can report an update to it here: Report update to this record